Symptom-Triggered Alcohol Detoxification Compared to Fixed-Dose Regimen of Benzodiazepines: A Retrospective...

Area of Science:

• Addiction Medicine
• Pharmacology
• Clinical Psychology

Background:

• Alcohol withdrawal syndrome (AWS) presents significant clinical challenges.
• Effective management of AWS is crucial to prevent severe complications.
• Symptom-triggered therapy (STT) offers a potential alternative to fixed-dose regimens (FDRs) for AWS management.

Purpose of the Study:

• To evaluate the effectiveness and safety of STT using the Hamburg Alcohol Withdrawal Scale (HAWS) compared to FDRs.
• To assess the impact of STT on benzodiazepine dosage, detoxification duration, and inpatient stay.
• To compare complication rates, including seizures and delirium tremens, between STT and FDRs.

Main Methods:

• A retrospective case-control study comparing STT with FDRs for inpatient alcohol detoxification.
• 123 patients in the STT group were matched with 123 controls in the FDR group.
• Outcomes measured included benzodiazepine dosage, detoxification phase duration, length of stay, and complication occurrence.

Main Results:

• STT resulted in significantly lower benzodiazepine dosage (22.50 mg vs. 115.00 mg) and shorter detoxification duration (48.00 h vs. 201.75 h).
• Patients on STT had a reduced length of inpatient stay (23.00 days vs. 28.00 days).
• No significant differences in complication rates were observed between STT and FDR groups, even after adjusting for covariates.

Conclusions:

• Symptom-triggered therapy (STT) is as effective and safe as fixed-dose regimens (FDRs) for inpatient alcohol detoxification.
• STT minimizes pharmacological exposure and facilitates earlier patient integration into psychosocial interventions.
• This approach holds potential for reducing healthcare costs associated with alcohol withdrawal management.